Trans-D Tropin’s® active constituents are all natural amino acids and fatty acids, combined with each other using an extraordinarily unique and technologically advanced process already highly sought after by several pharmaceutical companies in the past.
Essentially, the process to create Trans-D Tropin® mimics the in vivo process of protein conjugation. In other words, the process of producing Trans-D Tropin® is very similar to the way your body breaks down a turkey sandwich and then uses the amino acids to build up proteins in your body.
The result is an “analog” of GHRH or substance that acts like GHRH in the body. However, the constituent ingredients of Trans-D Tropin® are nothing more than amino acids and fatty acids. It is important to remember that it is NOT the ingredients, but rather HOW the ingredients are put together, that allow Trans-D Tropin® to work as effectively as it does (see below). The analogy would be having all the ingredients of the perfect cake, but if you don’t know HOW to mix the ingredients or how to bake the cake and put everything together, it will not come out looking or tasting the right way. Combined with the proprietary and innovative trans-dermal delivery mechanism, Trans-D Tropin® has now set a precedence by which all other similar products will be measured in the future.
The physiological concept:
The physiological approach utilized to formulate Trans-D Tropin® is of paramount importance. Rather than emulate the desired end product with a synthetic substance, the goal was to identify the messenger that would allow the body to increase the desired end product by increasing the body’s own production. Once identified, the messenger was mimicked and utilized to increase the desired end product endogenously.
In the case of Trans-D Tropin® , this approach allowed for the identification of the various hypothalamic specific poly-peptides (collectively referred to as hypothalamic poly-peptide combinants) which form GHRH. GHRH is responsible for the release of growth hormone from the pituitary. Thus, Trans-D Tropin® (various hypothalamic specific poly-peptide combinants) is a GHRH analog or mimicker, emulating the function of GHRH and resulting in an increase in the natural pulsatile release of endogenous GH.
The polypeptide sequencing technology:
The sequencing technology utilized to manufacture Trans-D Tropin® is far more advanced than any currently available and estimated by some scientists to be 15 to 20 years ahead of it’s time. Very simply, this technology allows for the creation of any poly-peptide sequence. In this specific case, it allows for the creation of hormonal messenger analogs, mimicking the action of the body’s own endogenous hormonal messengers. It is important to realize that simply blending amino acids or combining amino acid stacks will not accomplish the task achieved by Trans-D Tropin® (or any of the other unique trans-dermal poly-peptides by Balance Dermaceuticals® ).
To best understand this concept, think of your own body’s composition. If you take the exact chemical constituents that make up your own body down to every single component, add the necessary amount of water and bring the resulting concoction up to 98.7 degrees Fahrenheit, would you have a clone of yourself? How about another human? How about anything that even resembles life? The answer is, obviously not. However, the real question that must be asked is, what makes you physically different from the concoction that you just created? The answer: It’s “HOW” you were put together that makes you different from the concoction that you attempted to put together and NOT the ingredients. This is the reason why Trans-D Tropin® and the other trans-dermally delivered amino-acid (changed to polypeptide complexes in vivo) by Balance Dermaceuticals® are so efficacious. It is the unique method by “How” these amino acids are delivered and more importantly, how they assimilate and combine once they are introduced into the system that makes them so efficacious.
The trans-dermal delivery method:
A relatively uncharted area of science incorporates the utilization of EFAs (essential fatty acids) as a mechanical means of therapy, such as employment in a drug delivery system. Already, the delivery method for a number of unique experimental treatment modalities such as B Lymphocyte stimulators as well as established treatment modalities such as growth hormone releasing hormone analogs utilizing polypeptide synthesis technologies (Trans-D Tropin® ) have been achieved utilizing EFAs as the mode of transport. The delicate nature of these polypeptide sequences renders them susceptible to denaturing by gastrointestinal acids and digestive enzymes as well as the fact that our modern day society has created a tremendous vacillation in gut function and poor gut absorption. This results in preventing oral delivery mechanism from being a viable option. Conventional paraenteral routes (IV, IM or SQ injections) raise the issue of compliance due to the necessity for daily injections as well as the concern for convenience. The very sensitive nature of these polypeptide structures, which result in actions analogous to hormones, thus prevents traditional drug delivery mechanisms from being utilized.
Utilizing specific combinations of EFAs with other carrier substances, these new polypeptide treatment modalities now have a way of being delivered into the system in a trans-dermal manner without the concerns of denaturing or issues regarding compliance. Evito is one such trans-dermal delivery modality utilized to deliver the active constituents of Trans-D Tropin® . Furthermore, not only do these EFA trans-dermal transport delivery mechanisms allow for convenient dosing, but they have also been actually found to contribute to stabilizing the polypeptide structures. Not surprisingly, assimilation into the system is also achieved beyond that of other delivery mechanisms including other non-EFA trans-dermal delivery mechanisms.